ZIOPHARM Oncolgy

ZIOP NASDAQ
5.45
-0.46
-7.78%
Closed 17:55 06/24 EDT
Open
5.76
Prev Close
5.91
High
5.90
Low
5.39
Volume
3.11M
Avg Vol (3M)
1.76M
52 Week High
6.30
52 Week Low
1.560
% Turnover
1.92%
Market Cap
885.05M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers ZIOPHARM Oncolgy ZIOP stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
MORE >

Recently

Name
Price
%Change